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Purpose: To report the management of Vogt-Koyanagi-Harada (VKH) disease based 
on indocyanine green angiography (ICGA).
Methods: VKH patients with acute episodes of inflammation (inaugural or recurrent) 
who had received standard ICGA-guided care were studied retrospectively. Standard 
of care included high dose systemic corticosteroids at presentation and close ICGA 
follow-up with addition of immunosuppressive agents and/or intensification of 
ongoing therapy when recurrent choroidal lesions were detected by ICGA. Visual 
acuity, number of subclinical recurrences, type and duration of therapy, proportion 
of quiescent patients after therapy, and ICGA findings were recorded.
Results: Nine patients including 8 female and one male subject were studied. Five 
patients had inaugural disease and 4 presented with recurrent acute episodes. Visual 
acuity increased from 0.86±0.36 to 1.14±0.34 in the right eyes, and from 0.77±0.34 to 
1.05±0.33 in the left eyes. The number of ICGA-detected occult choroidal recurrences 
amounted to 13. Mean duration of treatment was 30.1±34.6 months leading to 
recurrence-free status after discontinuation of therapy in 6 cases with mean duration 
of 29.5 months.
Conclusion: Continuous monitoring and aggressive therapy guided by ICGA in VKH 
disease prolongs treatment as compared to textbook guidelines but offers the prospect 
of reaching inflammation-free status after discontinuation of therapy. Zero tolerance 
to subclinical choroidal inflammation avoids irremediable evolution towards sunset 
glow fundus in patients treated early after the initial acute inflammatory attack.
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INTRODUCTION
Vogt-Koyanagi-Harada (VKH) disease is 
a bilateral granulomatous choroiditis that 
invariably starts in the choroidal stroma and is 
therefore called a primary stromal choroiditis.1 
The inflammatory process may evolve silently 
in the choroid without being clinically detected. 
When the condition becomes clinically 
apparent, it initially presents as panuveitis or 
more frequently as a predominantly posterior 
uveitis with papillitis and exudative retinal 
detachments. The disease is an autoimmune 
T-helper 1 type reaction directed against 
melanocytes in the choroidal stroma which ICGA Guided Management of VKH; Bouchenaki and Herbort
242 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2011; Vol. 6, No. 4
explains its site of origin.2,3
The inflammatory reaction in VKH can 
sometimes be mild and remain subclinical, 
making its diagnosis difficult without sensitive 
investigational tests. Most of the time, however, 
the inflammatory reaction is hyperacute 
involving the retina, optic nerve, vitreous and 
anterior chamber. Although these structures 
are involved only as a consequence of primary 
choroidal inflammation, they are accessible to 
clinical examination and will render the disease 
clinically apparent by demonstrating classical 
signs of multiple exudative retinal detachments 
and papillitis. These clinical signs respond 
to inflammation suppressive therapy (IST) 
including high dose systemic corticosteroids, 
which is necessary for control of hyperacute 
disease.4-6 After initial aggressive IST, clinical 
disease is rapidly brought under control within 6 
to 16 weeks and treatment is then progressively 
tapered with a total treatment duration of 6 to 
9 months according to textbooks.7,8
Development of sunset glow fundus is 
reported in almost 100% of VKH cases, even 
when the disease seems to be under control 
clinically.9-11 Development of sunset glow 
fundus in the absence of clinically manifest 
disease suggests silently progressive choroidal 
inflammation and indicates that the post-acute 
treatment regimen may be insufficient.12
Before the development of indocyanine 
green angiography (ICGA), there was no 
sensitive method to detect subtle choroidal 
inflammation, and ultrasonography was the 
only imaging modality used for VKH disease by 
providing only gross information in pronounced 
disease. In contrast to ultrasonography, 
ICGA is sensitive enough to detect small 
inflammatory foci within the choroidal 
stroma as well as inflammation of choroidal 
stromal vessels.13 ICGA is currently the most 
appropriate method for investigating choroidal 
inflammatory diseases, as it is sensitive enough 
to demonstrate minimal and often, subclinical 
lesions of the choroid both in inaugural disease 
and in insufficiently treated disease.14-17 ICGA 
signs of acute VKH disease have been clearly 
standardized with four signs consistently 
present. These include early choroidal vessel 
hyperfluorescence, intermediate to late phase 
fuzziness of choroidal stromal vessels, disc 
hyperfluorescence, and hypofluorescent dark 
dots (HDDs).16 The contribution of ICGA is 
particularly useful in cases of suspected VKH 
disease without an acute onset which are 
usually seen at a later stage, when suboptimal 
therapy has already been initiated, as well as in 
cases without a complete set of signs in whom 
diagnosis is more difficult. In such cases, ICGA 
signs indicating choroidal inflammatory activity 
include HDDs and fuzziness of stromal vessels; 
the other two signs (early hyperfluorescent 
choroidal vessels and disc hyperfluorescence) 
are indicative of more acute disease.18-22
Choroidal disease in VKH is silently 
progressive; therefore to avoid late complications 
such as sunset glow fundus, the inflammation 
needs to be treated adequately. On the other 
hand, only ICGA monitoring allows detection of 
subclinical inflammation and correct orientation 
of treatment. Herein we report the results of 
ICGA-guided management of acute episodes 
(inaugural or recurrent) of VKH disease.
METHODS
Patients with a diagnosis of VKH disease in 
an acute stage (inaugural episode or acute 
recurrent disease) who were referred to the 
uveitis clinic of the Center for Ophthalmic 
Specialized Care (COS) from 1995 to 2010 were 
retrospectively studied.
All patients had a complete routine uveitis 
work-up as applied for patients with posterior 
uveitis. At each major visit a complete ocular 
examination was performed including Snellen 
visual acuity, slit lamp examination, applanation 
tonometry, dilated fundus examination, laser 
flare photometry, computerized visual field 
(VF) testing, optical coherence tomography 
(OCT) since available, and dual fluorescein 
angiography (FA) and ICGA. FA and ICGA 
were performed using a standard protocol as 
previously described.23 FA and ICGA were 
usually performed simultaneously. A Topcon 
50 IA camera (Topcon, Tokyo, Japan) coupled 
to the ImageNet (Topcon, Tokyo, Japan) image 
digitalizing system was used to acquire the ICGA Guided Management of VKH; Bouchenaki and Herbort
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images.
To exclude autofluorescence, evidence of 
pre-injection fluorescence was sought with 
the highest flash intensity used for ICGA. At 
the same time, red-free posterior pole frames 
were taken. After a bolus injection of 500 mg 
ICG (Cardiogreen; Peaselt, Lorei, Germany) 
diluted in 7.5 ml of 0.9% salt solution, ICGA 
frames of the posterior pole were taken up to 
2 to 3 minutes (early phase angiogram). ICG 
background fluorescence was analyzed in detail 
12±3 minutes after ICG injection (intermediate 
phase angiogram) by capturing posterior pole 
frames and a minimum of 8 frames from the 
whole periphery over 360°. At the end of the 
intermediate ICGA phase, FA was performed. 
Early fluorescein angiographic frames of the 
posterior pole were taken up to 2 minutes. 
Between 4 to 7 minutes, 360° panoramic imaging 
of the periphery was performed (minimum of 8 
frames), followed by late fluorescein posterior 
pole frames at 10 minutes. Late ICG background 
fluorescence was analyzed at 32±4 minutes after 
ICG injection (late phase angiogram) in the same 
fashion as that during the intermediate phase.
Laser flare assessment was performed 
using a Kowa FM-500 laser flare meter (Kowa 
Company, Ltd., Electronics and Optics Division, 
Tokyo, Japan) and OCT was performed using 
the OTI-Spectral OCT/SLO (OTI Inc., Toronto, 
Canada). For VF assessment the G1 program of 
the OCTOPUS 900 (Octopus 900, G Standard; 
Haag-Streit International, Bern, Switzerland) 
was used.
All patients underwent the standard of 
care of our center (Fig. 1) for treatment of acute 
active episodes of VKH disease (inaugural 
disease or acute recurrences) with very high 
dose oral corticosteroids (prednisone, 1.2-1.7 
mg/kg) or in case of hyperacute disease, a 
combination of intravenous methylprednisolone 
(1000 mg/day) for 3 days followed by high-
dose oral corticosteroids (prednisone, 1 mg/
kg). ICGA, according to the above mentioned 
protocol, was performed at presentation before 
initiating treatment and every month±1 week 
thereafter until disappearance of HDDs and 
normalization of choroidal vessels, at least 
up to 4 months after presentation. During the 
tapering phase of corticosteroids beyond 4 
months, ICGA was performed every 6±2 weeks. 
In case of subclinical reappearance of HDDs 
and/or fuzzy choroidal vessels, corticosteroid 
therapy was increased to 1mg/kg again and 
in parallel an immunosuppressant agent was 
added, azathioprine or mycophenolate mofetil 
usually being the first choice. Progressive 
tapering was then started again under ICGA 
control. Therapy was increased again by two 
steps each time ICGA signs reappeared.
Visual outcomes, proportion of cases 
having presented with subclinical recurrence, 
proportion of cases having needed additional 
Figure 1. (A) An example of ICGA-guided management 
of VKH. A patient with an inaugural episode of VKH 
disease shows numerous HDDs and complete vessel 
fuzziness (top left frames, ICGA-1). FA (top right 
frames, FA-1) shows disc hyperfluorescence and 
peripapillary exudative retinal detachment. After 
intravenous methylprednisolone and oral prednisone, 
there is complete disappearance of HDDs and fuzziness 
of choroidal vessels, the pattern of which is clearly seen 
again (bottom left frames, ICGA-2), while there is residual 
disc and peripapillary hyperfluorescence (bottom right 
frames, FA-2). (B) After prednisone tapering, subclinical 
recurrence of choroidal inflammation with reappearance 
of HDDs and fuzziness of choroidal vessels (top left 
frames, ICGA-3) are seen, while FA is quasi normal with 
only residual disc hyperfluorescence (top right frames, 
FA-3). After increase of oral prednisone and addition 
of mycophenolate mofetil, the choroidal inflammatory 
lesions (HDDs) disappeared two months later and 
choroidal vessels regained a normal appearance (bottom 
left frames, ICGA-4).
ICGA, indocyanine green angiography
VKH, Vogt-Koyanagi-Harada
HDDs, hypofluorescent dark dots
FA, fluorescein angiography
A BICGA Guided Management of VKH; Bouchenaki and Herbort
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immunosuppressive therapy, type and duration 
of therapy, quiescence of disease at the end of 
follow-up, course of fundus appearance, and 
presence and evolution of ICGA signs (ICGA 
sign free cases) were the main parameters 
analyzed in the study.
RESULTS
Out of 1,268 new patients seen at the uveitis 
clinic at the Center for Ophthalmic Specialized 
Care (COS), Lausanne, Switzerland from 1995 
to 2010, 22 (1.73%) subjects including 15 women 
and 7 men were diagnosed with VKH disease. 
Nine patients (1 man and 8 women) with mean 
age of 33.9±10.6 years had sufficient data to 
be included in the present study (Table 1). 
One patient had ICGA-guided follow-up who 
responded insufficiently to several treatments 
probably because of lack of compliance; this 
case was excluded from final analysis.
Five subjects were seen for an acute 
inaugural episode, 3 cases experienced an 
acute recurrence and had been initially treated 
at another center, and the ninth patient had 
uncontrollable disease. Mean duration from 
onset of symptoms (initial episode or acute 
recurrent attack) to initiation of therapy was 
19.1±13.1 days (excluding the ninth patient). 
Serous retinal detachment was seen in 7 of 9 
cases (Fig. 2); 8 of 9 patients had cerebrospinal 
fluid (CSF) pleocytosis. The patient with normal 
CSF was diagnosed 7 days after the onset of 
symptoms.
Mean visual acuity at presentation was 
0.86±0.36 and 0.77±0.34 in the right and left 
eyes respectively, and 1.14±0.34 and 1.05±0.33 
respectively at final follow-up.
The mean number of ICGA recurrences was 
2.1±1.4 episodes with 3 patients demonstrating 
no clinical or ICGA signs of recurrence after 
the initial high-dose treatment was tapered. 
Cases (Sex)
Age 
(Years)
Type of acute 
episode
F/U
(months)
ICGA signs
Early hyperfluorescent 
vessels
Disc 
hyperfluorescence
Fuzzy 
vessels
HDDs
Case 1 (F) 37 Inaugural Under therapy Yes No Yes Yes
Case 2 (F) 19 Recurrent 4 m Yes Yes Yes Yes
Case 3 (F) 31 Inaugural Lost to F/U  Yes Yes Yes Yes
Case 4 (F) 35 Inaugural 14 m Yes Yes Yes Yes
Case 5 (F) 24 Recurrent 114 m Yes Yes Yes Yes
Case 6 (M) 46 Inaugural 9 m Yes Yes Yes Yes
Case 7 (F) 51 Recurrent 28 m Yes Yes Yes Yes
Case 8 (F) 24 Inaugural 14 m No Unilateral Yes Yes
Case 9 (F) 38 Recurrent 132 m Yes Unilateral Yes Yes
Table 1. Demographic data, type of disease, follow-up period and ICGA findings
F, Female; M, Male; ICGA, indocyanine green angiography; F/U, follow-up; HDDs, hypofluorescent dark dots
Figure 2. Fundus and OCT findings in acute VKH. Fundus 
signs showed bilateral serous retinal detachments in this 
patient (only the left eye is shown) diagnosed 7 days after 
the onset of symptoms. OCT illustrates subretinal fluid 
at presentation (top scan, A). After 3 days of intravenous 
methylprednisolone, the amount of fluid has decreased 
substantially (middle scan, B) with quasi normalization 
after one month of treatment (bottom scan, C).
OCT, optical coherence tomography
VKH, Vogt-Koyanagi-HaradaICGA Guided Management of VKH; Bouchenaki and Herbort
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Excluding these 3 patients, the mean number 
of recurrences was 3.2±1.7 in the remaining 6 
patients. The total number of ICGA recurrences 
was 19, with 6 recurrences (all in one poorly 
responsive case) being both clinical and ICGA-
based.
All patients were treated using high-dose 
corticosteroid therapy, this included high-dose 
intravenous methylprednisolone (500-1000 mg 
daily) for 3 days in 4 of 9 patients, and oral 
prednisone (1.2-1.7 mg/kg) in the remaining. In 2 
of 9 (22%) patients no immunosuppressive agent 
was added and no recurrence occurred after 
slow tapering of steroids. In 7 of 9 patients (78%) 
however, immunosuppressive therapy was 
required in addition to prednisone therapy from 
the beginning. In one patient, azathioprine was 
added after one month because of corticosteroid 
intolerance and slow response to therapy based 
on ICGA findings. This patient experienced no 
recurrence after tapering treatment. In the 6 
remaining patients immunosuppressive agents 
had to be added because of recurrences during 
tapering of initial treatment. These included 
azathioprine (N=5), mycophenolate mofetil 
(N=4), cyclosporine (N=3), and infliximab, 
adalimumab and interferon-α (N=1 for each). 
Two patients required simultaneous use of two 
immunosuppressive agents and three patients 
received two immunosuppressants sequentially, 
i.e. azathioprine was replaced by the less toxic 
mycophenolate mofetil.
Mean total duration of therapy was 
30.1±34.6 (range, 9-114) months. In the patient 
resistant to therapy, treatment was administered 
continuously for 132 months. Six patients 
remained quiescent, developed no ICGA signs 
and were recurrence-free for a mean duration of 
29.5±22.7 months after cessation of treatment. 
One patient was lost to follow-up while still 
under treatment and recurrence-free for 6 
months and the other patient was still under 
treatment at the time of this report, 13 months 
after the acute episode.
Sunset glow fundus sign was present in 
4 of 9 patients, all of whom had experienced 
recurrences including the poorly responsive 
patient. In 5 other patients there were no 
sunset glow fundus signs, all of whom were 
first seen at the time of their inaugural acute 
Figure 3.  Early choroidal hyperfluorescent vessels 
three days after administration of intravenous 
methylprednisolone (top right) in a patient with 
an acute inaugural VKH episode at presentation 
(top left). Normalization of choroidal vessels after 3 
months of combined prednisone and mycophenolate 
mofetil therapy (bottom left, 3). Reappearance of early 
hyperfluorescent choroidal vessels, together with HDDs 
6 weeks later upon discontinuation of prednisone 
(bottom frames 4a and 4b).
VKH, Vogt-Koyanagi-Harada
HDDs, hypofluorescent dark dots
Figure 4. Numerous HDDs and fuzzy vessels at 
presentation (1). Decrease in HDDs after one month of 
prednisone therapy with persistence of fuzzy vessels 
observed with ICGA-guided follow-up (2). Choroidal 
inflammation finally responded to combined prednisone 
and mycophenolate mofetil therapy resulting in 
resolution of HDDs and restoration of normal pattern 
of choroidal vessels (3). Six weeks later and after 
discontinuation of prednisone, recurrence of occult 
choroidal inflammation was noted with reappearance of 
HDDs and vessel fuzziness in some areas of the fundus 
(4, crimson circles and arrows) which slowly responded 
to the addition of cyclosporine after two months (5) 
leading to a quasi normal choroidal appearance after 
another two months (6).
ICGA, indocyanine green angiography
HDDs, hypofluorescent dark dotsICGA Guided Management of VKH; Bouchenaki and Herbort
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episode. None of the patients showed late signs 
of disease such as poliosis, alopecia or vitiligo.
ICGA signs were identical whether the 
acute episode was inaugural or recurrent. At 
presentation, 8 of 9 patients showed early 
hyperfluorescent choroidal vessels (Fig. 1), 8 of 
9 subjects presented with disc hyperfluorescence 
which was unilateral in two, all cases showed 
fuzzy choroidal vessels bilaterally (Fig. 3) and 
bilateral round HDDs (Fig. 4). At the time of 
occult choroidal recurrence, HDDs and fuzziness 
of vessels were the only ICGA signs.
DISCUSSION
The initial pathological process in VKH disease 
starts within the choroidal stroma at the level of 
melanocytic islets and goes clinically undetected 
until inflammation affects neighboring 
structures including the retina and optic disc, 
usually in an acute or hyperacute fashion.24-26 
The standard of care is to start vigorous 
IST which classically consists of high-dose 
systemic corticosteroids tapered over a period 
of 6-9 months.7,8 The disease responds well to 
such an approach and clinical signs regress 
satisfactorily.27 Nevertheless, even in patients 
with apparently inactive disease, close to 100% 
of cases evolve towards sunset glow fundus.10,28 
This evolution towards depigmentation of the 
fundus despite apparently quiescent disease 
shows that persistent choroidal disease, albeit 
without clinical signs, is invariably present 
after clinical disease has been brought under 
control.29,30 Subclinical choroidal inflammation 
in posterior uveitides can only be detected by 
ICGA.31-38 This is the case for VKH at the onset 
of disease when no clinical signs are present 
yet, or after treatment once clinical disease has 
been mastered.14,22 It has been shown that in 
seemingly pure anterior recurrences of VKH, 
ICGA clearly shows subclinical choroidal 
lesions.17 We have also shown that insufficient 
therapy in the post-acute phase when clinical 
signs have resolved, fails to control choroidal 
lesions.15 The amount of evidence at our 
disposal on continuing smouldering choroidal 
inflammation clearly indicates that in order to 
extinguish VKH disease, subclinical choroidal 
inflammation has to be treated and the only 
way to assess and follow choroidal involvement 
is by using ICGA.
ICGA-guided therapy has been our standard 
of care since we used ICGA for posterior uveitis 
back in the early 90’s. The current study showed 
that in 8 patients, a number of 13 subclinical 
recurrences were detected by ICGA leading 
to reinforced and prolonged therapy. Mean 
duration of treatment in our series was 30 
months which is by far longer than indicated 
in textbooks.7,8 However the absence of sunset 
glow fundus in patients who had received 
ICGA-guided therapy since their inaugural 
episode justifies such an aggressive therapeutic 
approach. In contrast, all patients included for 
an acute recurrence developed sunset glow 
fundus (sometimes already present at inclusion) 
most certainly due to previous damage caused 
by ongoing smouldering subclinical choroidal 
inflammation. Furthermore, visual outcome 
was excellent for this group of VKH patients 
receiving ICGA-guided therapy. Such an 
aggressive and closely monitored attitude is 
further supported by the good proportion of 
patients in whom the disease remained quiescent 
after discontinuation of therapy with mean 
inflammation-free status exceeding two and a 
half years. This group of patients with quiescent 
disease included most of the patients in whom 
the acute episode had been a recurrence and 
sunset glow fundus was present. None of our 
patients developed late signs of VKH disease 
such as poliosis, vitiligo or alopecia indicating 
that zero tolerance even to low grade choroidal 
inflammation prevents evolution to late stage 
disease including sunset glow fundus in patients 
taken care of since the inaugural inflammatory 
episode. We believe that classification criteria39 
employing late signs are obsolete because they 
do not characterize late disease, in fact they 
reflect insufficiently treated disease.
ICGA signs have been standardized for 
early acute VKH disease and findings were 
found to be quite consistent.16 Four main ICGA 
signs have been suggested to assess choroidal 
involvement in acute episodes of VKH. These 
include (1) early hyperfluorescent choroidal 
vessels indicating acute choroidal vasculitis, ICGA Guided Management of VKH; Bouchenaki and Herbort
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(2) disc hyperfluorescence reflecting hyperacute 
disease, (3) fuzzy choroidal vessels seen in 
intermediate to early late phase frames denoting 
choroidal inflammatory vasculopathy, and (4) 
HDDs indicating foci of choroidal inflammation. 
All of these signs were present in our group 
of patients with acute inflammatory attacks, 
except in one patient who did not demonstrate 
disc hyperfluorescence and another patient 
who did not show early hyperfluorescent 
choroidal vessels. At the time of occult choroidal 
recurrence, the degree of inflammation is much 
less severe than the initial acute episode so that 
disc hyperfluorescence is never observed and 
early hyperfluorescent choroidal vessels were 
either absent or not clear-cut. All 13 episodes 
of occult recurrence were clearly identified 
by the reappearance of HDDs in parallel with 
fuzziness of choroidal vessels.
To meaningfully assess posterior uveitis 
nowadays, it is difficult to imagine not using 
ICGA when choroidal involvement is suspected. 
ICGA represents the only modality capable of 
identifying choroidal inflammation, hidden to 
other investigational modalities. This peculiarity 
of choroidal inflammation is characterized by 
the analogic angiographic concepts including the 
“iceberg effect” where most of the inflammatory 
process is not detectable by usual diagnostic 
means, and the “submarine effect” when only 
ICGA is positive and no other clue to choroidal 
inflammation exists. Obviously if choroidal 
inflammation can only be assessed by ICGA, 
monitoring of its evolution and adjustment of 
therapy can also only be performed by ICGA 
follow-up, as was illustrated in this study.
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